Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04341675 · ClinicalTrials.gov registry record · Phase 2
Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia
A Phase 2 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT04341675 is a Phase 2 study that has completed, run by University of Cincinnati. The registered enrollment target is 32 participants.
The verdict
NCT04341675, a Phase 2 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The main objective of our study is to determine if treatment with sirolimus can improve clinical outcomes in hospitalized patients with COVID-19. The investigators will employ a randomized, double blind, placebo-controlled study design. 28 subjects were randomized in a 2:1 fashion to receive sirolimus or placebo. Sirolimus will be given as a 6mg oral loading dose on day 1 followed by 2mg daily for a maximum treatment duration of 14 days or until hospital discharge, whichever happens sooner. Chart reviews will be conducted daily to determine changes in clinical status, concomitant medications and laboratory parameters. Study specific biomarkers will be measured at baseline and then at days 3, 7 and 14.
Interventions
- DRUG Sirolimus
- DRUG Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-04-24 |
| Est. Completion | 2020-09-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04341675
The ClinicalTrials.gov registry entry for NCT04341675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sirolimus is the first listed.
NCT04341675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04341675 about?
NCT04341675 is a clinical study titled "Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia". The main objective of our study is to determine if treatment with sirolimus can improve clinical outcomes in hospitalized patients with COVID-19. The investigators will employ a randomized, double blind, placebo-controlled study design. 28 subjects were randomized in a 2:1 fashion to receive sirolim...
What is the current status of trial NCT04341675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2020-04-24. Estimated completion is 2020-09-15.
What interventions are being tested in trial NCT04341675?
The interventions under investigation include: Sirolimus (DRUG), Placebo (DRUG).
Who is sponsoring clinical trial NCT04341675?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.